Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its Q3 2020 financial and operating results after U.S. markets close on November 5, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its Q3 2020 financial and operating results after U.S. markets close on November 5, 2020. Management will host a conference call and live webcast at 4:30 PM ET to discuss results and provide a corporate update. Investors can participate by calling (855) 779-9075 or (631) 485-4866 for international access, using conference ID 8125409. The event will be accessible on Xenon’s website and available for replay for 30 days.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +6.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, November 5, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 8125409. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.